{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:28:57Z","timestamp":1770431337696,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.eururo.2007.05.027","type":"journal-article","created":{"date-parts":[[2007,6,7]],"date-time":"2007-06-07T15:36:40Z","timestamp":1181230600000},"page":"1195-1203","source":"Crossref","is-referenced-by-count":60,"title":["Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg"],"prefix":"10.1016","volume":"52","author":[{"given":"Christopher R.","family":"Chapple","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aino","family":"Fianu-Jonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Indig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vik","family":"Khullar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto M.","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Mark","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Bolodeoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2007.05.027_bib1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"issue":"Suppl 6A","key":"10.1016\/j.eururo.2007.05.027_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0090-4295(97)00580-3","article-title":"The patient with overactive bladder \u2013 symptoms and quality-of-life issues","volume":"50","author":"Jackson","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2007.05.027_bib3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1742-1241.2006.01057.x","article-title":"Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care","volume":"60","author":"Odeyemi","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2007.05.027_bib4","doi-asserted-by":"crossref","unstructured":"Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006:CD003781.","DOI":"10.1002\/14651858.CD003781.pub2"},{"key":"10.1016\/j.eururo.2007.05.027_bib5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","article-title":"Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome","volume":"47","author":"Haab","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.05.027_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2005.06.007","article-title":"Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis","volume":"48","author":"Abrams","year":"2005","journal-title":"Eur Urol"},{"issue":"Suppl 5A","key":"10.1016\/j.eururo.2007.05.027_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0090-4295(99)00492-6","article-title":"Muscarinic receptor antagonists in the treatment of overactive bladder","volume":"55","author":"Chapple","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2007.05.027_bib8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.05.027_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","article-title":"Randomised, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2007.05.027_bib10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomised, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA study","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.eururo.2007.05.027_bib11","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1471-0528.1997.tb12054.x","article-title":"A medium-term analysis of the subjective efficacy of treatment of women with detrusor instability and low bladder compliance","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.eururo.2007.05.027_bib12","first-page":"580","article-title":"Comparison of persistence among therapies for overactive bladder: a retrospective pharmacy claims analysis","volume":"24","author":"Cisternas","year":"2005","journal-title":"Neurourol Urodyn"},{"issue":"3 Suppl 1","key":"10.1016\/j.eururo.2007.05.027_bib13","first-page":"245","article-title":"Pharmacologic management of overactive bladder: practical options for the primary care physician","volume":"119","author":"Staskin","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.eururo.2007.05.027_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2007.05.027_bib15","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1046\/j.1532-5415.2001.49179.x","article-title":"Self reported and emotional impact of urinary incontinence","volume":"49","author":"Fultz","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.eururo.2007.05.027_bib16","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0149-2918(01)80126-0","article-title":"Factors associated with clinical assessment of overactive bladder and selection of treatment","volume":"23","author":"Diokno","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.eururo.2007.05.027_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0090-4295(97)00623-7","article-title":"Economic cost of urinary incontinence in 1995","volume":"51","author":"Wagner","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2007.05.027_bib18","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.eururo.2006.04.018","article-title":"The current and future burden and cost of overactive bladder in five European countries","volume":"50","author":"Reeves","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2007.05.027_bib19","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0149-2918(01)80104-1","article-title":"Coping strategies and health care-seeking behaviour in a US national sample of adults with symptoms suggestive of overactive bladder","volume":"23","author":"Ricci","year":"2001","journal-title":"Clin Ther"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283807007610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283807007610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,6]],"date-time":"2019-01-06T15:55:08Z","timestamp":1546790108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283807007610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0302283807007610"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2007.05.027","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}